Prostate Cancer Daily

June 04, 2026

Videos

Peer-to-Peer Clinical Conversations

Lutetium-177 PSMA-617 Therapy Across the Prostate Cancer Spectrum: Mechanism, Formulation, and Future Directions - Phillip Koo

Phillip Koo

Phillip Koo explains the mechanistic components of radioligand therapy, describing how the isotope, chelator, and targeting agent each independently influence biodistribution and efficacy.

View

PAM50 Intrinsic Subtyping and Salvage Therapy Decisions After Prostatectomy - Jonathan Tward

Jonathan Tward

Jonathan Tward presents data using PAM50 molecular classifier in 130 post-prostatectomy biochemical recurrence patients receiving salvage radiation.

View

Beyond the Abstracts

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the Abstract

Robotic-Assisted Radical Prostatectomy in Patients 80+ Years: A Multi-Centre Experience - Beyond the Abstract

Conference Coverage

SNMMI 2026: Olaparib Sensitizes Prostate Cancer to 177Lu-PSMA-617 Radioligand Therapy via Suppression of Glycolysis

ASCO 2026: Discussant - Minimizing Toxicity and Maximizing Patient Benefit in Prostate Cancer

ASCO 2026: Cognitive Effects of Darolutamide vs Enzalutamide: Results of ARACOG (AFT-47), a Randomized Clinical Trial from the Alliance for Clinical Trials in Oncology

ASCO 2026: A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to Androgen Receptor Pathway Inhibitor in mHSPC (A-DREAM / Alliance A032101)

ASCO 2026: Discussant - Precision Oncology: How to Apply New Biomarkers in Clinical Practice

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer.

Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis.

Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management.

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.

One-Year Functional Satisfaction and Quality of Life Outcomes of Patients With a History of Radiotherapy With Artificial Urinary Sphincters.

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login